Cancer Res Treat.  2015 Apr;47(2):215-220. 10.4143/crt.2013.262.

Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort

• Lee YG
• Bang SM
• Lee JO
• Kim JW
• Lee KW
• Kim JH
• Song JH
• Kim TH
• Kim KW
• Lee JS

• KMID: 2132800
• DOI: http://doi.org/10.4143/crt.2013.262

Abstract

PURPOSE
We previously reported the prevalence of monoclonal gammopathy of undetermined significance (MGUS) to be 3.3% among an elderly Korean urban cohort recruited during 2005-2006. Here, we report a 5-year follow-up study of the previously identified MGUS cohort.
MATERIALS AND METHODS
The 680 participants from the initial cohort were followed-up for a median of 5 years. Sera were collected between 2010 and 2011. Two-step screening was performed with standard serum electrophoresis followed by immunofixation and determination of the serum concentration of monoclonal-protein (M-protein).
RESULTS
Of the 680 participants (21 with MGUS), 348 (51%) agreed to participate in the follow-up study and 10 were found to have MGUS. Among the 21 MGUS patients initially identified, nine were followed-up, six had persistent M-protein, and one patient had progressed to multiple myeloma (progression rate, 1.0%/yr). The M-protein disappeared in the remaining two individuals. Among the 339 participants without MGUS who were followed-up, four developed an M-protein. There was no significant difference in survival with respect to the presence of MGUS (p=0.66).
CONCLUSION
The 5-year follow-up data show that the natural clinical course of MGUS in Korea is similar to that in Western countries. MGUS was not associated with an increased risk of death over the 5-year study period.

Keyword

Monoclonal gammopathy of undetermined significance; Prevalence; Follow-up studies

MeSH Terms

Aged*
Cohort Studies*
Electrophoresis
Follow-Up Studies*
Humans
Korea
Mass Screening
Monoclonal Gammopathy of Undetermined Significance*
Multiple Myeloma
Prevalence

Figure

• 

  Fig. 1. Follow-up of 680 participants. MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma.

• 

  Fig. 2. Overall survival by the presence of monoclonal gammopathy of undetermined significance (MGUS).

Reference

References

1. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009; 113:5418–22.

2. Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc. 2010; 85:933–42.

3. Neriishi K, Nakashima E, Suzuki G. Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma. Br J Haematol. 2003; 121:405–10.

4. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002; 346:564–9.

5. Gregersen H, Ibsen J, Mellemkjoer L, Dahlerup J, Olsen J, Sorensen HT. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol. 2001; 112:353–7.

6. Park HK, Lee KR, Kim YJ, Cho HI, Kim JE, Kim KW, et al. Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population. Am J Hematol. 2011; 86:752–5.

7. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007; 82:1468–73.

8. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006; 107:904–6.

9. Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 2010; 116:1056–9.

10. Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc. 2007; 82:1474–9.

11. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354:1362–9.

12. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003; 102:3759–64.

13. Blade J, Rosinol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia. 2008; 22:1651–7.

14. Varettoni M, Corso A, Cocito F, Mangiacavalli S, Pascutto C, Zappasodi P, et al. Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients. Medicine (Baltimore). 2010; 89:211–6.

15. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc. 2004; 79:859–66.